共 50 条
- [21] Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival [J]. European Radiology, 2023, 33 : 7284 - 7293
- [22] Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib [J]. Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1963 - 1969
- [29] Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 612 - 623
- [30] A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients [J]. AAPS JOURNAL, 2015, 17 (06): : 1483 - 1491